Lyme disease: Shoot at Shots

22:29
Lyme disease: Shoot at Shots -

Congress is floundering in trouble whether people with Lyme disease should receive long-term antibiotic or if the drugs affect more help. This question, which has been an inexhaustible source of friction among biomedical researchers between researchers and patient-advocates get congressional hearings next year.

If there was a Nobel prize for disease-causes extreme controversy, Lyme disease is a serious contender. For years, the disease transmitted by ticks has been the subject of vicious battles between scientists and patient advocates about whether long-term antibiotics can help. Many affected by the disease that yes, citing the decline of symptoms after treatment; Many scientists say no, and several clinical trials save.

Now enter the fray Lyme is representative Frank Wolf (R-VA), who used to oversee the funding from the National Science Foundation of the United States and other scientific bodies as a powerful President of Committee expenses when Republicans controlled the House of representatives. In September, he sent a letter to the Ministry of Health and Social Services of the United States, demanding it investigate the guidelines of the Infectious Diseases Society of America (IDSA), which avoids long-term antibiotics treatment. He also requested that Congress hearings as soon as possible keeping subcommittee, and the office of Frank Pallone, Jr. (D-NJ), who chairs the House energy panel and the Subcommittee on Commerce Health said they will occur next year. "We want an independent assessment" of treatment guidelines, Wolf said in an interview with Science . Patients' lost the confidence of people travel for miles to get treatment. "

"I do not think" the IDSA guidelines should be used, he continued, "but I'm not a scientist. "IDSA, no stranger to tumult, said he is happy to cooperate with all audiences, but maintains its recommendations. In fact, IDSA has recently begun to assemble an independent group of eight to 12 people to review its guidelines for . treatment Lyme A spokesman said Science Insider "We have taken that extra step to say," Okay [if] you do not believe us, we will put it for review. "

Note: Commenter swampcrawler stresses that the decision of IDSA to conduct a review of its guidelines was part of an agreement with the Attorney General of Connecticut in May

(corrected Point 15/12/08)

Previous
Next Post »
0 Komentar